North America Tissue Diagnostics Market

North America Tissue Diagnostics Market Size (2023 to 2028)

The size of the Tissue Diagnostics Market in North America is estimated at USD 1.45 billion in 2023. It is estimated to be growing at a CAGR of 6.6% to reach USD 2.00 billion by 2028. Increasing adoption of personalized medicine, substantial funds, and investments for R & D are significantly contributing to the market's growth. 

Growth in the IVD’s, increasing aging population and rising death rate of cancer, and accelerating healthcare expenditure are majorly boosting the tissue diagnostics market in North America. Creating awareness in people to motivate initial diagnosis and monitoring are significant steps for early identification of cancer and is expected to favor the market growth. Developing infrastructure for cancer diagnosis and availability of reimbursement scenarios are a big plus to the growth rate of the market during the forecast timespan.

Restraints such as financial constraints and a high degree of consolidation are likely to hamper the market growth. Moreover, the high cost involving the deployment and high perforation is to inhibit the market growth. 

Covid-19 is spreading all over the world very rapidly, creating a critical impact on the economy. The tissue diagnostics market is affected positively by the COVID-19. These tissue diagnostics find utilization in identifying the presence of the virus among the patients. 

This research report on the North America Tissue Diagnostics Market has been segmented and sub-segmented into the following categories:

By Product Type: 

• Instruments
  • Microscope
  • Non-contact Handheld IR Thermometer
  • Haemocytometer
  • NMR Tube
  • Others
• Consumables
  • Reagent kits
  • Others

By Disease: 

• Lung Cancer
• Lymphoma
• Pancreatic Cancer
• Breast Cancer
• Others

By Application: 

• Immunohistochemistry
• Hematoxylin and Eosin
• In-Situ Hybridization

By End User: 

• Contract Research Organizations
• Hospitals
• Diagnostic Laboratories
• Research Organizations
• Biotechnology Companies

By Country: 

• The U.S.
• Canada
• Rest of North America

Regionally, the Tissue diagnostics market was dominated by North America due to the prevalence of cancer and health literacy supported by modern diagnostic techniques available.

The U.S. is leading the North American market in terms of revenue and growing R&D activities to develop diagnostics. Y-O-Y growth in cancer patients, developing healthcare infrastructure, enhanced insurance coverage, and reimbursement policies, which surge up the market growth in this region. 

The Canadian market is the second leading country in the North American market and is expected to grow at a healthy CAGR during the forecast period. Increasing death cases, rising support from government and other private organizations, and critical players bolster the market. Moreover, the healthcare expenses are more in this country, where the country has spent nearly 253.5 billion USD for healthcare and is predicted to rise due to healthcare reforms and government policies. The government pays almost 70% of the healthcare cost for ease of diagnosis and treatment.

Companies playing a dominant role in the North America Tissue diagnostics Market profiled in this report are F. Hoffmann-La Roche AG, Sigma-Aldrich Co. LLC, Abbott Laboratories, Agilent Technologies, BioGenex, Danaher Corporation, Cell Signaling Technology, and Ventana Medical Systems.